Pantoprazole vs Rabeprazole
## Overview
Pantoprazole and rabeprazole share the distinction of being the two PPIs with the least CYP2C19 inhibitory activity, making both preferable over omeprazole/esomeprazole/lansoprazole in patients on clopidogrel or other CYP2C19-sensitive drugs.
## Mechanism of Action
Both irreversibly block H+/K+-ATPase. Rabeprazole activates faster in the parietal cell; pantoprazole has a distinct binding site fingerprint (Cys813 + Cys822).
## Pharmacokinetics
Pantoprazole: CYP2C19 + CYP3A4 metabolism but minimal CYP2C19 inhibition; IV formulation available. Rabeprazole: primarily non-enzymatic hydrolysis; no IV formulation.
## Clinical Preference
Both are preferred over other PPIs when CYP2C19 drug interactions must be minimized. Pantoprazole is often chosen in hospital settings due to its IV formulation. Rabeprazole is preferred in East Asian populations (high CYP2C19 UM prevalence) where consistent acid suppression is needed.
## Key Takeaways
- Both minimal CYP2C19 inhibition — preferred with clopidogrel
- Pantoprazole: IV formulation; rabeprazole: fastest oral onset
- Rabeprazole: non-enzymatic elimination, most consistent across genotypes
結論
Both pantoprazole and rabeprazole are the safest PPIs regarding CYP2C19 drug interactions. Pantoprazole is preferred in hospitalized patients requiring IV PPI therapy. Rabeprazole is preferred when oral therapy is sufficient and CYP2C19 ultra-rapid metabolizer status is a concern.